Pediatric Nephrology

, Volume 27, Issue 5, pp 727–732 | Cite as

New developments in the treatment of systemic lupus erythematosus

Review

Abstract

A large number of new studies on the treatment of systemic lupus erythematosus (SLE) have recently been or are about to be published. Unfortunately, all these studies have been performed in adult patients and there are no studies in children. There is, however, a strong need for more effective drugs with, if possible, fewer side-effects also in children. We do thus need to carefully asses the studies in adult patients to evaluate which of the new drugs can be tried in children with severe lupus nephritis. Some of the new studies have been largely confirmatory, such as demonstrating the efficacy of mycophenolate mofetil in the treatment of SLE, but others have been surprising, such as the lack of efficacy of rituximab. The debate as to why the rituximab studies got negative results is ongoing. Lastly, there is an emergence of novel medications for the treatment of SLE, mostly monoclonal antibodies targeting various aspects of the immune system: belimumab, an antibody affecting B-cell function, is likely to become the first new drug registered for lupus for many years as several large randomized studies have shown significant (albeit not dramatic) responses to this antibody. Many other drugs are in the pipeline and will hopefully come to the clinical arena. This review aims to give a critical appraisal of the plethora of studies in the context of the clinical reality of a pediatric nephrologist treating patients with SLE.

Keywords

Lupus SLE Nephritis Mycophenolate mofetil Rituximab Belimumab Drug treatment 

References

  1. 1.
    Zetterstrom R, Berglund G (1956) Systemic lupus erythematosus in childhood; a clinical study. Acta Paediatr 45:189–204PubMedCrossRefGoogle Scholar
  2. 2.
    Cameron JS (1994) Lupus nephritis in childhood and adolescence. Pediatr Nephrol 8:230–249PubMedCrossRefGoogle Scholar
  3. 3.
    Hagelberg S, Lee Y, Bargman J, Mah G, Schneider R, Laskin C, Eddy A, Gladman D, Urowitz M, Hebert D, Silverman E (2002) Long-term follow-up of childhood lupus nephritis. J Rheumatol 29:2635–2642PubMedGoogle Scholar
  4. 4.
    Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, Lau CS, Wong AK, Tong MK, Chan KW, Lai KN (2000) Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 343:1156–1162PubMedCrossRefGoogle Scholar
  5. 5.
    Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O’Nan P, Roth D (2004) Sequential therapies for proliferative lupus nephritis. N Engl J Med 350:971–980PubMedCrossRefGoogle Scholar
  6. 6.
    Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysler E, Sanchez-Guerrero J, Solomons N, Wofsy D (2009) Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 20:1103–1112PubMedCrossRefGoogle Scholar
  7. 7.
    Ginzler EM, Wofsy D, Isenberg D, Gordon C, Lisk L, Dooley MA (2010) Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. Arthritis Rheum 62:211–221PubMedCrossRefGoogle Scholar
  8. 8.
    Isenberg D, Appel GB, Contreras G, Dooley MA, Ginzler EM, Jayne D, Sanchez-Guerrero J, Wofsy D, Yu X, Solomons N (2010) Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford) 49:128–140CrossRefGoogle Scholar
  9. 9.
    Radhakrishnan J, Moutzouris DA, Ginzler EM, Solomons N, Siempos II, Appel GB (2010) Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int 77:152–160PubMedCrossRefGoogle Scholar
  10. 10.
    Wofsy D, Appel GB, Dooley M, Ginzler E, Isenberg D, Jayne D, Salomon NLL, for the ALMS Study Group (2010) Aspreva lupus management study (ALMS) maintenance results. 9th International Congress on Systemic Lupus Erythematosus, Vancouver, Canada, June 24–27, Poster PO2 E23Google Scholar
  11. 11.
    Houssiau FA, D’Cruz D, Sangle S, Remy P, Vasconcelos C, Petrovic R, Fiehn C, de Ramon GE, Gilboe IM, Tektonidou M, Blockmans D, Ravelingien I, le Guern V, Depresseux G, Guillevin L, Cervera R (2010) Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis 69:2083–2089PubMedCrossRefGoogle Scholar
  12. 12.
    Touma Z, Gladman DD, Urowitz MB, Beyene J, Uleryk EM, Shah PS (2011) Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis. J Rheumatol 38:69–78PubMedCrossRefGoogle Scholar
  13. 13.
    Kazyra I, Pilkington C, Marks SD, Tullus K (2010) Mycophenolate mofetil treatment in children and adolescents with lupus. Arch Dis Child 95:1059–1061PubMedCrossRefGoogle Scholar
  14. 14.
    Marks SD, Tullus K (2010) Modern therapeutic strategies for paediatric systemic lupus erythematosus and lupus nephritis. Acta Paediatr 99:967–974PubMedCrossRefGoogle Scholar
  15. 15.
    Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG (2010) Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 62:222–233PubMedCrossRefGoogle Scholar
  16. 16.
    Furie R, Looney J, Rovin B, Latinis K, Appel G, Sanchez-Guerrero J, Fervenza F, Maciuca R, Zhang D, Garg J, Brunetta P, and the LUNAR study group (2010) Efficacy and safety of rituximab in patients with proliferative lupus nephritis: results from the randomized, double-blind phase III LUNAR study. 9th International Congress on Systemic Lupus Erythematosus, Vancouver, Canada, June 24–27, Poster PO2 E 6Google Scholar
  17. 17.
    Furie R, Rovin B, Appel G, Kamen D, Fervenza F, Spindler A, Maciuca R, Garg J, Brunetta P, and the LUNAR study group (2010) Effect of rituximab on anti-double-stranded DNA antibody and C3 levels and relationship to response: results from the LUNAR trial. 9th International Congress on Systemic Lupus Erythematosus, Vancouver, Canada, June 24–27, Poster PO2 E 22Google Scholar
  18. 18.
    Mysler E, Spindler A, Guzman R, Bijl M, Jayne D, Furie R, Maciuca R, Drappa J, Shahdad S, Close D (2010) Study design and baseline patient characteristics of BELONG, the randomized double-blind, placebo-controlled phase III trial of ocrelizumab, a humanized anti-CD20 antibody, in lupus nephritis. 9th International Congress on Systemic Lupus Erythematosus, Vancouver, Canada, June 24–27, Poster PO2 E 20Google Scholar
  19. 19.
    Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, Li EK, Thomas M, Kim HY, Leon MG, Tanasescu C, Nasonov E, Lan JL, Pineda L, Zhong ZJ, Freimuth W, Petri MA (2011) Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377:721–731PubMedCrossRefGoogle Scholar
  20. 20.
    Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, Petri MA, Ginzler EM, Chatham WW, McCune WJ, Fernandez V, Chevrier MR, Zhong ZJ, Freimuth WW (2009) A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 61:1168–1178PubMedCrossRefGoogle Scholar
  21. 21.
    Petri M, Wallace D, Furie R, Merrill J, Ginzler E, Stohl W, Chatham W, McCune J, Weinstein A, Klein J, Zhong Z, Freimuth W, for the LBSL02/99 study group (2010) Five-year experience with Belimumab, a BLyS-specific inhibitor, in patients with systemic lupus erythematosus (SLE). 9th International Congress on Systemic Lupus Erythematosus, Vancouver, Canada, June 24–27, Poster PO2 EGoogle Scholar
  22. 22.
    Furie R (2010) Belimumab, a BlyS-specific inhibitor, reduced disease activity and severe flares in patients with seropositive SLE: BLISS-76 Study. 9th International Congress on Systemic Lupus Erythematosus, Vancouver, Canada, June 24–27Google Scholar
  23. 23.
    Dorner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, Burmester GR (2006) Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 8:R74PubMedCrossRefGoogle Scholar
  24. 24.
    Press release, UCB, Rome 16th 2010; http://www.ucb.com/_up/ucb_com_news/document. Accessed 10 Nov 2010
  25. 25.
    Pena-Rossi C, Nasonov E, Stanislav M, Yakusevich V, Ershova O, Lomareva N, Saunders H, Hill J, Nestorov I (2009) An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus. Lupus 18:547–555PubMedCrossRefGoogle Scholar
  26. 26.
    Cardiel MH, Tumlin JA, Furie RA, Wallace DJ, Joh T, Linnik MD (2008) Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial. Arthritis Rheum 58:2470–2480PubMedCrossRefGoogle Scholar
  27. 27.
    Aringer M, Houssiau F, Gordon C, Graninger WB, Voll RE, Rath E, Steiner G, Smolen JS (2009) Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology (Oxford) 48:1451–1454CrossRefGoogle Scholar
  28. 28.
    Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, Fleisher T, Balow JE, Lipsky PE (2010) Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 62:542–552PubMedCrossRefGoogle Scholar
  29. 29.
    Merrill JT, Burgos-Vargas R, Westhovens R, Chalmers A, D’Cruz D, Wallace DJ, Bae SC, Sigal L, Becker JC, Kelly S, Raghupathi K, Li T, Peng Y, Kinaszczuk M, Nash P (2010) The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 62:3077–3087PubMedCrossRefGoogle Scholar
  30. 30.
    D’Andrea D, Xie F, Zimmer R (2010) A randomized, double-blind, placebo-controlled study of spliceosomal peptide rigerimod in patients with systemic lupus erythematosus (SLE). 9th International Congress on Systemic Lupus Erythematosus, Vancouver, Canada, June 24–27, Poster PO2 EGoogle Scholar

Copyright information

© IPNA 2011

Authors and Affiliations

  1. 1.Great Ormond Street Hospital for ChildrenLondonUK

Personalised recommendations